A Further Milestone Achieved: The AIDA Still’s Disease Registry Surpasses 600-Patient Mark

The AIDA Network proudly announces another significant achievement in the field of autoinflammatory diseases: the AIDA Still’s Disease Registry has now surpassed the remarkable milestone of 600 enrolled patients. This outstanding accomplishment highlights the power of international collaboration in generating high-quality real-world data to enhance the understanding and management of Still's disease.

Since its inception a little over two years ago, the AIDA Still’s Disease Registry has played a pivotal role in advancing clinical research. To date, 11 scientific articles have already been published utilizing data from this registry, providing invaluable insights into the disease’s pathogenesis, clinical manifestations, and therapeutic strategies. Moreover, numerous research projects are currently underway, further strengthening the scientific foundation for personalized patient care.

The rapid growth of the registry is a testament to the increasing number of specialized centers joining the AIDA Network. With each new participating center, the breadth and depth of collected data expand, offering a more comprehensive and globally representative picture of Still's disease. This steady rise in patient enrollment fuels continuous advancements in clinical knowledge and therapeutic approaches, ultimately benefiting patients worldwide.

Thanks to this large-scale data collection, the AIDA Network is poised to conduct robust studies that address key unmet clinical needs. The integration of real-world data from diverse geographical and clinical settings ensures a holistic understanding of Still's disease, transcending the limitations of single-center studies. This achievement not only deepens scientific knowledge but also paves the way for innovative, patient-centered treatment strategies.

The enrollment of over 600 patients in the AIDA Still’s Disease Registry marks an exciting step forward in scientific progress. This milestone will facilitate groundbreaking discoveries and drive improvements in patient care. A heartfelt thanks goes to all the investigators and centers that have contributed to this success, as well as to those who will continue to support and expand this ambitious project. Together, we are shaping the future of Still's disease research and patient management.